Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, January 23, 2013
CAMO Software, leaders in multivariate data analysis solutions, today announced the release of a new version of the Unscrambler® X Process Pulse software for process monitoring. The software is designed to be used by laboratory staff, technical ...
read more
Wednesday, December 30, 2020
Relaxera Pharmazeutische Gesellschaft mbH & Co. KG and CBL Patras announce the signing of an exclusive contract for human relaxin-2.
read more
ReiThera, Leukocare, and Univercells announced a collaboration for the development and largescale manufacturing of a novel adenoviral vector-based vaccine against COVID-19.
read more
ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies, and Exothera, a full-service Contract Development and Manufacturing...
read more
Regis Technologies has announced a new capability of Solid State Chemistry.
read more
REGENXBIO has selected Skyland PIMS Process Information Management Suite for management and analysis of product, process and patient data throughout their development and manufacturing supply chain.
read more
Friday, September 11, 2020
REGENXBIO has dosed the first patient in its trial to evaluate the suprachoroidal delivery of RGX-314 using Clearside’s SCS Microinjector for the treatment of wet AMD.
read more
Thursday, August 02, 2018
RegeneRx Biopharmaceuticals announced its licensee for RGN-137, GtreeBNT, has entered into a joint venture with YuYang DNU to develop RGN-137 on a global basis for the orphan indication, epidermolysis bullosa.
read more
Regeneron and Zai Lab announced a collaboration for the development and commercialization of REGN1979 in mainland China, Hong Kong, Taiwan and Macau.
read more
Thursday, August 20, 2020
Regeneron and Roche are working together to develop, manufacture and distribute REGN-COV2, Regeneron's investigational anti-viral antibody cocktail.
read more
Wednesday, August 09, 2023
Regeneron Pharmaceuticals and Decibel Therapeutics announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4.00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable ...
read more
Regeneron Pharmaceuticals announced a clinical and supply agreement for a Phase 1b dose-escalation study in renal cell carcinoma.
read more
Monday, February 10, 2020
ReForm Biologics and MilliporeSigma announced a global license agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations.
read more
ReForm Biologics announced the appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to the company’s Scientific Advisory Board (SAB).
read more
ReForm Biologics has expanded its patent portfolio with the issuance of U.S. Patent No. 10,279,048 (the ‘048 patent).
read more